The molecule is imiquimod (Graceway Pharmaceuticals' Aldara) which is a TLR7 agonist and Anadys announced on July that it is resuming clinical investigation of the TLR7 mechanism for the treatment of HCV.
Anadys believes that ANA773 can overcome GI hurdles with a prodrug formulation that masks the active TLR7 metabolite in the gut, thereby preventing exposure to gut immune tissue and reducing tox that killed its 1st generation TLR7 agent - ANA975.
Market Data 
Markets 
AI
